Effect of administration low dose aspirin on pregnancy outcome

Effect of low dose Aspirin in Prevention of Adverse Pregnancy Outcomes in Women with Unexplained Elevated alpha-protein in second trimester screening

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014042017365N1

Enrollment

200

Registered

2015-05-05

Start date

2013-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Preeclampsia. Condition 2: Preterm Labar. Condition 3: IUGR. Condition 4: Intra Uterine Fetal Death. Condition 5: Addmision in NICU or Neonatal Ward. Gestationa l(pregnancy induced) hypertension with significant proteinuria Preterm spontaneous labour with preterm delivery Usually referred to as weight below but length above 10th centile for gestational age. Intra Uterine Fetal Death Ernal complication of pregnancy, unspecified

Interventions

No additional treatment for control group

Intervention 1: Low dose Aspirin (80 mg) administrated from study time until 34 weeks of pregnancy, compared with control group (no Aspirin). Intervention 2: No additional treatment for control group.

Treatment - Drugs

Diagnosis

Low dose Aspirin (80 mg) administrated from study time until 34 weeks of pregnancy, compared with control group (no Aspirin)

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Pregnant women with Second-trimester positive screening test for Neural Tube Defect and alpha-fetoprotein = 2.5 MOM. Exclusion criteria: Women with positive Thrombophili; Thrombocytopenia; Structural or Chromosomal anomalies of the fetus; Placental hematoma; Early severe IUGR; Multiple pregnancies; Ultrasonographic sign of cervical incompetency.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Neonatal weight respect of gestational age at delivery. Timepoint: Post delivery. Method of measurement: Wight of neonate less than 10 % percentile for gestational age and sign of IUGR.;Gestational age at delivery. Timepoint: Past delivery. Method of measurement: Birth of neonate before 37 complete weeks.;Neonatal admision time. Timepoint: Past delivery. Method of measurement: Days of neonatal admission in neonatal ward or neonatal intensive care unit.;Fetal daeth. Timepoint: Visits in pregnancy. Method of measurement: Non live fetus in uterine period after 20 weeks of gestational age.;Preeclampsia. Timepoint: Prenatal visits. Method of measurement: Maternal blood presure of>= 140/90 plus proteinuria (>300 milligram in 24 hours urine).	—

Measure

Time frame

Neonatal weight respect of gestational age at delivery. Timepoint: Post delivery. Method of measurement: Wight of neonate less than 10 % percentile for gestational age and sign of IUGR.;Gestational age at delivery. Timepoint: Past delivery. Method of measurement: Birth of neonate before 37 complete weeks.;Neonatal admision time. Timepoint: Past delivery. Method of measurement: Days of neonatal admission in neonatal ward or neonatal intensive care unit.;Fetal daeth. Timepoint: Visits in pregnancy. Method of measurement: Non live fetus in uterine period after 20 weeks of gestational age.;Preeclampsia. Timepoint: Prenatal visits. Method of measurement: Maternal blood presure of>= 140/90 plus proteinuria (>300 milligram in 24 hours urine).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahadori Fatemeh

Urmia University of Medical Sciences

fbahadory27@yahoo.com+98 44 3223 7077

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026